The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
 
Minh Duc Phan
No Relationships to Disclose
 
Paul Antoine El Tomb
No Relationships to Disclose
 
Tariq Khreis
No Relationships to Disclose
 
Tobias Meissner
Stock and Other Ownership Interests - Sema4
Research Funding - Cellworks (Inst); Sema4 (Inst)
 
Rachel Elsey
Consulting or Advisory Role - VieCure
Research Funding - Sema4 (Inst)
 
Bing Xu
No Relationships to Disclose
 
Junaid Arshad
Honoraria - Aptitude Health
Consulting or Advisory Role - Novartis Pharmaceuticals UK Ltd.
 
Umbreen Arshad Rozell
Consulting or Advisory Role - Aptitude Health; Curio Science
 
Elysia Tjong
No Relationships to Disclose
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte
 
Sonam Puri
Honoraria - Aptitude Health (Inst); IntegrityCE
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Arsalan Khan
No Relationships to Disclose
 
Dorothy Rhoades
Research Funding - American Cancer Society (Inst)
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Regeneron
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Adanma Ayanambakkam
No Relationships to Disclose
 
Anthony Burtman
No Relationships to Disclose
 
Mark Bigbey
No Relationships to Disclose
 
Michael Sjoquist
No Relationships to Disclose
 
Casey B. Williams
Employment - Genentech/Roche (I)
Stock and Other Ownership Interests - Genentech (I); Sema4
Consulting or Advisory Role - Sema4; Takeda; VieCure
Research Funding - Kiadis Pharma (Inst); Sema4 (Inst); Takeda (Inst); Tesaro (Inst)
 
Abdul Rafeh Naqash
No Relationships to Disclose